Kodiak Sciences Inc. (KOD) Stock Analysis — April 2026 Rating, Price, and Forecast
Company Overview — What Does Kodiak Sciences Inc. Do?
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is KSI-301, an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet inhibitor for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California. Kodiak Sciences Inc. (KOD) is classified as a mid-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Victor Perlroth and employs approximately 90 people. With a market capitalization of $2.6B, KOD is one of the notable companies in the Healthcare sector.
Kodiak Sciences Inc. (KOD) Stock Rating — Reduce (April 2026)
As of April 2026, Kodiak Sciences Inc. receives a Reduce rating with a composite score of 32.3/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.KOD ranks #2,175 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Kodiak Sciences Inc. ranks #252 of 838 stocks, placing it in the upper half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).
KOD Stock Price and 52-Week Range
Kodiak Sciences Inc. (KOD) currently trades at $43.00. The stock gained $0.64 (1.5%) in the most recent trading session. The 52-week high for KOD is $31.18, which means the stock is currently trading 37.9% from its annual peak. The 52-week low is $1.92, putting the stock 2139.6% above its annual trough. Recent trading volume was 0 shares, suggesting relatively thin trading activity.
Is KOD Overvalued or Undervalued? — Valuation Analysis
Kodiak Sciences Inc. (KOD) carries a value factor score of 25/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 16.42x, versus the sector average of 2.75x.
At current multiples, Kodiak Sciences Inc. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.
Kodiak Sciences Inc. Profitability — ROE, Margins, and Quality Score
Kodiak Sciences Inc. (KOD) earns a quality factor score of 16/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -138.0%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -61.8% versus the sector average of -33.1%.
Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.
KOD Debt, Balance Sheet, and Financial Health
Kodiak Sciences Inc. has a debt-to-equity ratio of 123.0%, compared to the Healthcare sector average of 32.0%. Leverage is within a manageable range for the industry, though investors should monitor debt trends over time. The current ratio is 4.72x, indicating strong short-term liquidity. Total debt on the balance sheet is $0. Cash and equivalents stand at $72M.
KOD has a beta of 1.54, meaning it is more volatile than the broader market — a $10,000 investment in KOD would be expected to move 53.7% more than the S&P 500 on any given day. The stability factor score for Kodiak Sciences Inc. is 17/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.
Kodiak Sciences Inc. Revenue and Earnings History — Quarterly Trend
In TTM 2026, Kodiak Sciences Inc. reported revenue of $0 and earnings per share (EPS) of $-4.32. Net income for the quarter was $-217M. Operating income came in at $-224M.
In FY 2025, Kodiak Sciences Inc. reported revenue of $0 and earnings per share (EPS) of $-4.32. Net income for the quarter was $-230M. Operating income came in at $-234M.
In Q3 2025, Kodiak Sciences Inc. reported revenue of $0 and earnings per share (EPS) of $-1.16. Net income for the quarter was $-61M. Operating income came in at $-62M.
In Q2 2025, Kodiak Sciences Inc. reported revenue of $0 and earnings per share (EPS) of $-1.03. Net income for the quarter was $-54M. Operating income came in at $-56M.
Over the past 8 quarters, Kodiak Sciences Inc. has experienced revenue contraction from $0 to $0. Investors analyzing KOD stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.
KOD Dividend Yield and Income Analysis
Kodiak Sciences Inc. (KOD) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.
KOD Momentum and Technical Analysis Profile
Kodiak Sciences Inc. (KOD) has a momentum factor score of 78/100, indicating strong price momentum with the stock outperforming the majority of the market over recent periods. Stocks with high momentum scores have historically tended to continue their outperformance in the near term. The investment factor score is 25/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 2/100 signals elevated short interest, which can indicate bearish sentiment among institutional investors.
KOD vs Competitors — Healthcare Sector Ranking and Peer Comparison
Within the Healthcare sector, Kodiak Sciences Inc. (KOD) ranks #252 out of 838 stocks based on the Blank Capital composite score. This places KOD in the upper half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.
Comparing KOD against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full KOD vs S&P 500 (SPY) comparison to assess how Kodiak Sciences Inc. stacks up against the broader market across all factor dimensions.
KOD Next Earnings Date
No upcoming earnings date has been announced for Kodiak Sciences Inc. (KOD) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.
Should You Buy KOD? — Investment Thesis Summary
The quantitative profile for Kodiak Sciences Inc. suggests caution. The quality score of 16/100 flags below-average profitability. The value score of 25/100 indicates premium valuation. Price momentum is positive at 78/100, suggesting the trend favors buyers. High volatility (stability score 17/100) increases portfolio risk.
In summary, Kodiak Sciences Inc. (KOD) earns a Reduce rating with a composite score of 32.3/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on KOD stock.
Related Resources for KOD Investors
Explore more research and tools: KOD vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare KOD head-to-head with peers: KOD vs AZN, KOD vs SLGL, KOD vs VMD.